Post

Breyanzi battles CAR-T rivals with back-to-back approvals in lymphoma

On 15 May 2024, Bristol Myers Squibb (BMS) announced accelerated FDA approval of its agent Breyanzi (lisocabtagene maraleucel) for adults …

ASCO 2024: J&J’s early radioligand prostate cancer trial reports four patient deaths

Johnson & Johnson’s (J&J) prostate cancer radiotherapy JNJ-6420 outlook was hampered by safety issues that resulted in four deaths in …

OCT East Coast: Patient centricity begins with understanding the patient

With patient-driven clinical trials being a focal point of the 15th Annual Outsourcing in Clinical Trials East Coast conference, experts …

ASCO 2024: Rakuten’s photoimmunotherapy and Keytruda combo shows efficacy in HNSCC

US-based Rakuten Medical has announced positive interim data from the Phase Ib/II trial of its photoimmunotherapy, ASP-1929, in combination with …

Study investigating digital inhaler in children starts in UK

A National Health Service (NHS) funded study has launched in the UK, investigating whether the use of a smart inhaler …